Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 801–900 of 1,086
Al-Joubory, G. S. N., & Hussain, M. A. (2026) · SAS Journal of Medicine · doi:10.36347/sasjm.2026.v12i04.009
Abegaz, T. M., Frietze, G. A., Bhagavathula, A. S., & Ali, A. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103060
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
Cardiac Magnetic Resonance to Define Myocardial Structure in Obesity-Associated Heart Failure
Cutts, J. A., Epstein, F. H., & Patel, A. R. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02372-6
“This may provide a possible explanation for the reduction in cardiac events noted in the Tirzepatide for Heart Failure with Pre-served Ejection Fraction study [11, 12].”
Mortada, I., Quach, V., Lee, A. W., Long, N., Ebel, G., Al‐Abdouh, A., Albayyaa, M., Love, A. N., Mansour, S., Chatila, K., et al. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105384
“9 Accordingly, we conducted a retrospective cohort study to examine the association between tirzepa-tide use and 1-year clinical cardiorenal outcomes in obese patients following TAVR.”
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review
Bihelek, N., Burke, S., & Barry, A. R. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag121
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · Research Square · doi:10.21203/rs.3.rs-9407045/v1
Skeletal Muscle in Heart Failure
Shah, A., Scheetz, S. D., & Baliga, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00183-7
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Zhang, J. K., Gao, G., He, M., & Sun, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178921
Hou, Y., Zhao, J., Tang, Y., Liu, T., Zhang, Z., Wang, Z., & Shen, H. (2026) · iMetaMed · doi:10.1002/imm3.70042
Seijas‐Amigo, J., Salgado‐Barreira, Á., Roca-Martinez, C., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., et al. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.03.012 · Cited by 1
Biegus, J. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag131
Metabolic–inflammatory burden predicts mortality in heart failure across population and ICU cohorts
Zhang, K., & Sun, F. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200648
“Metabolic stress and chronic inflammation are believed to play critical roles in myocardial remodeling, mitochondrial dysfunction, and endothelial damage [17 – 20].”
Black, N., Soltani, F., Bradley, J., Williams, S. G., Reid, A. B., Nucifora, G., Schmitt, M., Petrie, M. C., & Miller, C. (2026) · Cureus · doi:10.7759/cureus.108732
“Such modelling needs to be revisited now that several effective treatments for HFpEF are available, including sodium-glucose cotransporter 2 inhibitors [25,26], glucagon-like 1 peptide receptor agonists [27,28], and mineralocorticoid receptor antagonists [29].”
Endocrine aspects of pharmacotherapy for chronic heart failure
Ждан, В. М., Volchenko, H. V., Babanina, М. Y., Kіtura, Y. M., Tkachenko, M. V., Kyrian, O. A., Ivanitsky, I. V., & Lebed, V. G. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1716
Abedi, M. M., Alabid, I., Alghoul, W. I. I., Salama, R. A. A., Lami, K. A. H. A., Marzougui, H., Swalha, B. R. R., Shaikh, S. A., Khan, S. S., & Mohamed, N. A. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103767
“Significant questions also remain regarding long-term disease course modification, optimal patient selection, and the best ways to integrate these therapies into clinical practice [12,13,44].”
InfluentialUpadhyay, N., Batra, K., Le, L., Steffens, A., Carlyle, M., Song, R., Horstman, T., Ye, W., & Plat, A. W. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101939
“[11 – 13].”
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Estler, B., Fröhlich, H., Täger, T., Heins, J., Frey, N., & Frankenstein, L. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134560
Losordo, L. D., Amin, G., Singla, M., Belk, S. S., Butler, K. R., Booz, G. W., & Monafo, A. (2026) · Pediatric Research · doi:10.1038/s41390-026-05038-9
Wachter, R., Seferović, P. M., & Laufs, U. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag174
Chaparala, P., Rongali, D. A., Khot, M., Rangachari, B., Ahmed, K. U., Suri, S., Greeshma, M., & Shafiq, M. M. (2026) · Cureus · doi:10.7759/cureus.109350
“Three additional studies were retained for narrative cardiovascular synthesis: Packer et al. [21], Zile et al. [22], and Wilson et al. [23].”
The emerging role of branched-chain amino acid metabolism in obesity
Wang, D., Wang, X., & Yang, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02103-5
“…plasma concentrations of BCAAs, BCKAs, and other BCAA-derived metabolites [132] and also decreased the composite risk of cardiovascular death or worsening heart failure, signi fi cantly improving patients ’ exercise tolerance and quality of life, while reducing systemic in fl ammatory markers [133].”
Mihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
“Additional analyses suggest a reduction in the relative risk of cardiovascular death or worsening heart failure, although event numbers remain limited [59,61].”
Valinotti, E., Vera, L. D. V., Ovelar, H. L., Gómez, F. R., Benítez, A. G., Mendieta, F. F., & Fernández, N. L. G. (2026) · Scripta Scientia · doi:10.66201/ss.v1.26
“En la ICFEp —condición hasta hace poco carente de terapias mo-dificadoras de la enfermedad—, la demostración de beneficios clínicamente significativos con tirzepatida en el ensayo SUMMIT (22) representa un cambio de paradigma (23).”
Das, B. B. (2026) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_85_26
Efeitos metabólicos, hormonais e anti-inflamatórios da tirzepatida na saúde endometrial feminina
de Sousa, E. R., & da Cunha, T. N. (2022) · South American Sciences · doi:10.52755/sas.v6i1.217
Tirzepatide data: safety first is safety always!
Janić, M., Rabbani, S. A., El‐Tanani, M., Rangraze, I. R., Janež, A., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2681511
CARDIOPROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A REVIEW OF RANDOMIZED CLINICAL TRIALS
Zaikina, Т. S., Рынчак, П. И., & Tytova, G. Y. (2026) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2026-2-181-62-67
Choi, H., & Hwang, A. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70903
GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss
Ryan, D. H. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005113
Gaffey, A. E., & Moura, F. A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101690
“For the everyday clinician, reassuringly there is now evidence for similar reductions in LDL-C with evinacumab in both females and males with HoFH.”
Diabetes Mellitus and the Heart
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3079
Hemdev, V., Abuzenah, M., Alsaafin, Q., Ghananeem, Z. A., Diksha, F., & Khatak, A. (2026) · Cureus · doi:10.7759/cureus.109953
Obesity and Outcomes in Heart Failure
Özkan, B., Neeland, I. J., & Ndumele, C. E. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.001
GLP-1 receptor agonists: from glycaemic control to cardio-reno-metabolic disease modification
Farmakis, D. T., Karampinos, K. I., & Filippatos, G. S. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag096
Incretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Christophides, T., Figlioli, G., Christoforou, S., Ioannou, K., Kounnafi, M., Piovani, D., Bonovas, S., & Nikolopoulos, G. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124450
“[7,15–20, 22, 24 ].”
InfluentialFerreira, V. M., & Muller, V. A. (2026) · Cureus · doi:10.7759/cureus.110621
“GLP-1 RAs significantly reduced ACM across seven studies: SUMMIT [11], FIGHT [12], LIVE [23], SELECT HF [26], SOUL HF [27], LEADER HF [31], and EXSCEL by EF [29] (HR 0.86, 95% CI 0.79-0.95; P=0.008; I²=0%), with a PI of 0.75 to 1.00.”
InfluentialPharmacological treatment of obstructive sleep apnea syndrome
Tardov, M. V., Boldin, A. V., Афанасьевич, Ф. А., Kotidis, I. M., Бокова, И. А., Tardova, V. M., & Bokova, O. A. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612605248 · Cited by 1
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“These findings suggest a potential disease-modifying role for incretin–based therapies in obesity-related heart failure, although longer-term outcome data remain limited [66, 79–82].”
Mashtoub, E. A., Hteit, A., Bedran, A., Banna, J. A., Hachem, C. E., OBEID, N., Msheik, M., Tlais, M., & Abdulaal, R. (2026) · World Journal of Meta-Analysis · doi:10.13105/wjma.v14.i2.119849
Immunology of Cardiometabolic Health and Disease: From Novelty to Necessity
DAY, E. D., Dick, S. A., Epelman, S., Dobrev, D., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.06.005
Vahle, B., Weidner, S., Tomalka, A., Schauer, A., Augstein, A., Männel, A., Barthel, P., Friedrich, J., Beck, G. C., Labeit, S., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014397
Pharmakotherapie der chronischen Herzinsuffizienz
Oexner, R. R., & Frantz, S. (2026) · Kardiologie up2date · doi:10.1055/a-2701-0826
Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF ≥40%
Feng, S., & Jin, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1880045
“The event reduction was driven mainly by fewer worsening HF events, and the trial should not be interpreted as definitive evidence for a stand-alone cardiovascular mortality benefit (57).”
Alterations in Cardiac and Systemic Metabolism in Heart Failure
Bertero, E., Capone, F., Costa, A., Maack, C., & Ameri, P. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013766 · Cited by 1
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
“…agonists of GLP-1 and glucose-dependent insulinotropic peptide (GIP) have been shown to be effective in managing blood glucose levels, reducing body weight and preventing events of worsening heart failure and CV death in patients with obesity and heart failure with preserved ejection fraction [40].”
Phenotypic Characterization of Unclassified Pulmonary Hypertension
Reddy, Y. N. V., Frantz, R. P., Egbe, A. C., Miranda, W. R., Asokan, A. K., Hassoun, P. M., Hemnes, A. R., Horn, E. M., Leopold, J. A., Rischard, F. P., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.014480
Self-citationZeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?
Peyer, J. G. (2026) · Nature Aging · doi:10.1038/s43587-026-01165-4
Diastolic dysfunction and diabetes: the DIADAD study—a retrospective cohort study from Liverpool
Wali, L., Abbara, M. A., Ekhelikar, S., Pilling, J., Albouaini, K., & Murray, S. W. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag079
Packer, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag211
Self-citationPeptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Qadeer, A., Khalid, M. B., Syed, R., Jain, S., Zakaria, F., Khan, M. H. A., Gohar, N., Shoukat, A., Mortada, I., Hamza, I., et al. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261465360
“14 Apart from glycemic control and weight loss properties, the mechanism of GLP-1/GIP RAs that protects from cardiovascular events is multifaceted.”
Venkataramanan, S. V. A. (2026) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2026.06.005
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Obesity, inflammation and HFpEF: Parts of the same circulus vitiosus
Milisavljević, K., Petrović, A., Jelić, F., Zdravković, D., & Zdravkovic, M. D. (2026) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk7-65653
Diagnostic Tests for Stage B Heart Failure
Dang, H. N. N., Luong, T. V., Huynh, Q. L., & Marwick, T. H. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02389-x
“These include individuals with hypertension [14, 15], diabetes mellitus [16, 17], obesity [15, 18], and chronic kidney disease [19, 20], which represent the most common substrates for subclinical HF. Advancing age is strongly associated with SBHF, with a particularly high prevalence among older…”
Spiazzi, B. F., Zingano, C. P., & Vest, A. R. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.06.025
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
“…but improvements in symptoms, exercise function, inflammatory markers, and heart failure events suggest that incretin-based therapy may also modify the inflammatory, hemodynamic, and functional phenotype of obesity-related HFpEF rather than acting only through weight reduction [13-15].”
InfluentialUpdates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
“Similarly, the SUM-MIT trial reported that tirzepatide improved quality of life in HFpEF patients and reduced the risk of worsening HF or cardiovascular death [183].”
Patel, J., Patel, D., & Pino, M. (2026) · Cureus · doi:10.7759/cureus.112239
Writing Task Force iCARDIO-Alliance (2026) · Global Cardiology · doi:10.4081/cardio.2026.111
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure
Mortada, I., Paul, K., Chammany, M., Abraham, Y., Devulapally, K., Lee, A. W., Mansour, S., Chatila, K., Boyars, M. C., Jehle, D. V., et al. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261467888
“8,13 Importantly, this association persisted across HF phenotypes in our study, with consistent reductions in hospitalization observed in both patients with HFrEF and those with HFnonrEF.”
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“These effects may arise from adiposity reduction, anti-inflammatory activity, and cardiac workload reduction [34].”
Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances
Duru, P., Tasouli-Drakou, V., Ramazani, N., Hartnett, S., Cyrus, T., & Tak, T. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8884
Tristan, C. D., Irnizarifka, I., Kynaya, E. M., Gani, M., Wijayanto, M. A., Asrial, A. A., & Pranata, R. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00812-w
“Conversely, the STEP-HFpEF and SUMMIT trial demonstrated significant improvements in symptoms and overall function in those with HFpEF [10, 40].”
Distinct Exercise Response Patterns in Patients With Heart Failure With Preserved Ejection Fraction
Schutter, S. D., Pugliese, N. R., Meems, L. M. G., Ferreira, S. M., Biase, N. D., Punta, L. D., Masi, S., Stassen, J., Herbots, L., Claessen, G., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.050524
“47 Both traditional weight loss strategies, SGLT2i, and these novel metabolic agents effectively reduce epicardial adipose tissue.”
Selvadurai, M. V., Dagan, M., Mariani, J. A., Vizi, D., Dewar, E., Kaye, D. M., & Nanayakkara, S. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.006
Breakthrough drugs in the treatment of hypertension-related disease
Hoshide, S., Mogi, M., Shibata, S., Kishi, T., Usui, I., Ando, H., Nakagami, H., Nishiyama, A., Kario, K., & Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management (2026) · Hypertension Research · doi:10.1038/s41440-026-02725-2
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8847
Research Progress of Tirzepatide in Metabolic Diseases
孙, 豪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672603
Naser, J. A., Copciag, R., Scott, C. G., Ibrahim, H. H., Kennedy, A. M., Egbe, A. C., Michelena, H. I., Pellikka, P. A., Nkomo, V. T., Miranda, W. R., et al. (2026) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2026.06.012
Gustafson, S. E., Patel, S. R., Fudim, M., Mentz, R. J., Sauer, A. J., Lala, A., Harrington, J., Pandey, A., Svetlichnaya, J., Fitzpatrick, J. K., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10653-z
“In contrast, glucagon-like peptide-1 (GLP-1) receptor agonists have shown improved symptoms and functional capacity in patients with obese HFpEF [ 43–45].”
Khatami, S., Faghihi, M., Tavakoli, G., Szmit, S., & Yousefifard, M. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10119-6
“While GLP-1–based therapies should not yet be prescribed solely for cardioprotection, their dual metabolic and cardiovascular profile, along with wide - spread clinical availability, make them particularly suitable for translational investigation [ 8, 19, 42 – 44, 75 , 76 ].”
Lari, S. A., Zumot, M. S., & Alrashid, M. A. (2026) · Cureus · doi:10.7759/cureus.112694
“These robust cardioprotective data suggest that remaining on standard single-pathway therapy when an effective step-up option is available may leave patients unnecessarily vulnerable to heart failure progression and systemic vascular complications [1,17,19].”
InfluentialExamining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Chan, T. C., Brennan, J. J., Killeen, J. P., & Castillo, E. M. (2026) · Emergency Care and Medicine · doi:10.3390/ecm3030022
“Large clinical trials have demonstrated the beneficial impact GLP-1s on atherosclerotic disease, including lower rates of heart disease and failure, myocardial infarction, and stroke, particularly in patients with diabetes [25,26].”
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
Rashid, M., Lee, E. L., Veettil, S. K., Dhippayom, T., Cheng, A. Y. Y., SIMONETTI, J. S., & Chaiyakunapruk, N. (2026) · Obesity Reviews · doi:10.1111/obr.70198
Haring, B., Iaconelli, A., Perera, D., Velazquez, E. J., Murphy, G. J., Barbato, E., Maron, D. J., Metra, M., Adamopoulos, S. N., Petrie, M. C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag230
Dai, F., & Dai, Y. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03310-0
Belančić, A., Majanović, S. K., Skroče, K., Ciudin, A., & Borovac, J. A. (2026) · Medicina · doi:10.3390/medicina62081446
“These considerations should restrain overgener-alization while not diminishing the genuine therapeutic progress represented by current trials [42,48,49,63].”
InfluentialClinical Implications of Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction
Ibe, T., Naser, J. A., Harada, T., Tada, A., DOI, S., Reddy, Y. N. V., Melenovský, V., Jensen, M. D., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.014
Self-citationSoloveva, A. E., Park, J. J., Apostolou, E., Böhm, M., Cannata, A. N., Fudim, M., Kittipibul, V., Mueller, S., Potapova, K., Schattenberg, J. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag243
Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?
Dorjee, T., Hawkins, N. M., Moghaddam, N., Elliott, M. D., & Levin, A. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001170
Pack, S. J.-J., Sawant, S., Abhayaratna, C., & Wang, N. (2026) · Heart · doi:10.1136/heartjnl-2026-327872
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag043
Tirzepatide and cardiovascular outcomes
Dani, S. S., Jayakumar, A., & Ganatra, S. (2026) · BMJ · doi:10.1136/bmj-2026-100366
Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications
Fan, H., Wu, J., Shen, Y., & Zheng, W. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s613343
Chen, S. C., & Chen, Y.-T. (2026) · Research Square · doi:10.21203/rs.3.rs-9855917/v1
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction
Beavers, C. J., & Greene, S. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10656-w
“Early changes in plasma volume, in NT-proBNP, and relatively early improvement in symptoms before significant weight loss—all suggest a cardiac-specific effect of GLP-1 RA, in addition to overall benefits from weight loss [ 62, 63 , 65 ].”
Influential
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.